Quality Analysis of Different Kinds of Trial-Processed Tea from Tea Germplasm with Almond-like Aroma in Guangxi

To evaluate the tea processing suitability of the leaves of ‘Guixing’ tea, a wild tea plant germplasm resource in Guangxi, the water extract content, polyphenolic composition, sensory properties and volatile aroma composition of the tea leaves as well as green, oolong, white and black tea processed from the tea leaves were measured and compared with each other. The results showed that ‘Guixing’ tea was a unique tea germplasm resource with low caffeine content and a ratio of phenol to ammonia of 11.8, which was more suitable for black tea production. After processing into white and black tea, the epigallocatechin content in the leaves decreased to 0, and the catechin content of green tea decreased significantly compared with that of the leaves. The results of sensory evaluation showed that white and black tea had a rich almond-like aroma, while the other kinds of tea did not. A total of 53 aroma components were detected, which could be divided into two types. Each type had same aroma components. The first type included tea leaves, green tea and oolong tea, without almond-like aroma, and had 40 aroma components, the major ones being β-linalool and limonene. The second type included white tea and black tea, with strong almond-like aroma, and contained 42 aroma components, the main one being benzaldehyde. A total of 28 aroma components were found to be common to these tea samples, all of which contained benzaldehyde. The decreasing order of the relative contents of benzaldehyde in them was black tea (61.97%) > white tea (31.73%) > oolong tea (14.65%) > leaves (4.24%) > green tea (2.88%). Benzaldehyde was mainly produced during withering, rolling and fermentation. With extended withering time, the content of benzaldehyde increased. The higher the content of benzaldehyde, the stronger the almond-like aroma of tea. Therefore, benzaldehyde is key for almond-like aroma formation

Risk analysis and assessment based on Sigma metrics and intended use

Introduction: In order to ensure the quality in clinical laboratories and meet the low risk requirements of patients and clinicians, a risk analysis and assessment model based on Sigma metrics and intended use was constructed, based on which differential sigma performance (σ) expectations of 42 analytes were developed. Materials and methods: Failure mode and effects analysis was applied to produce an analytic risk rating based on three factors, each test of which was graded as follows: 1) Sigma metrics; 2) the severity of harm; 3) intended use. By multiplying the score of Sigma metrics by the score of severity of harm by the score of intended use, each was assigned a typical risk priority number (RPN), with RPN ≤ 25 rated as low risk. Low risk was defined as acceptable standards; the sigma performance expectations were calculated. Results: Among the 42 analytes, tests with σ ≥ 6, 5 ≤ σ < 6, 4 ≤ σ < 5, 3 ≤ σ < 4, σ < 3 were 21, 5, 5, 6, and 5, respectively; there were 7 high-risk tests, 8 of them medium risk tests. According to the risk assessment conclusion, 13 tests had sigma performance expectations ≥ 6; 15 test items had sigma performance expectations ≥ 5, while 3 test items had sigma performance expectations ≥ 4; 11 test items had sigma performance expectations ≥ 3. Conclusions: Constructing the risk analysis and assessment model based on Sigma metrics and intended use will help clinical laboratories to identify the high-risk tests more objectively and comprehensively. Such model can also be used to establish the sigma performance expectations and meet the low risk requirements of patients and clinicians

Global Infectious Diseases in December 2022: Monthly Analysis

The emergence and reoccurrence of infectious diseases constitute a significant threat to human health. Data for this paper were mainly obtained from official websites, such as the WHO and national CDC websites. The report summarizes and analyzes information on infectious diseases for early outbreak monitoring from 24 November to 23 December 2022. Monkeypox cases declined in December 2022 with few deaths, while cholera infections have increased in African regions and war-torn countries. Most sub-Saharan countries are affected by insect-borne diseases, such as dengue, Lassa, and chikungunya fever

Global Infectious Diseases in August 2023: A Monthly Analysis

Infectious diseases frequently affect children and adults worldwide. Owing to their specific biology and mode of transmission, the presence of infected individuals or carriers in a region often leads to outbreaks of the disease in that region, and in severe cases, to the death of the infected individual. Infectious diseases have been one of the main causes of mass disability or death in humans for centuries. Surveillance of infectious diseases on a continental scale is therefore important for assessing, recognizing, and preventing the risks that these diseases may pose to animal and human health on a global scale. This report focuses on global infectious disease outbreaks and systematically summarises the timing and location of outbreaks in infected populations between 24 July and 23 August 2023 based on the Global Outbreak Information Surveillance System (GOSIS) of Shusi Technologies

Global Infectious Diseases in June 2023: Monthly Analysis

Infectious diseases are a class of diseases caused by various pathogens that can be transmitted between humans and animals or between humans and animals, thus seriously affecting the development of human society. To control the spread of infectious diseases worldwide and ensure the safety of people’s lives, it is essential to regularly analyze global infectious disease cases. This review is based on data from the World Health Organization, the Centers for Disease Control in countries around the world, Outbreak News Today and many other epidemiological websites to predict the global infectious disease outbreak trend. In addition, using the Shuci Technology global epidemic information monitoring system, we analyzed the distribution of infectious diseases that occurred around the world from 24 May 2023 to 23 June 2023

Global Infectious Diseases in March 2023: Monthly Analysis

Infectious diseases pose a major burden on public health and economic stability among societies worldwide. For centuries, they have been among the leading causes of death and disability, and are currently presenting growing challenges to health security and human progress. This report focuses on global outbreaks of infectious diseases, relying on Shusi Tech’s Global Epidemic Information Monitoring System to systematically summarize outbreak timing and location in infected populations from February 24, 2023, to March 23, 2023. Therefore, surveillance of infectious diseases on a continental scale is important to assess, recognize and protect against the risks that these diseases may pose to animal, domestic animal and human health on a global scale

Global Infectious Diseases in November 2022: Monthly Analysis

Infectious diseases, such as COVID-19 and monkeypox, pose a severe threat to economic development in all countries, as well as to the health of people everywhere. The World Health Organization and National Health Council epidemiological websites were used herein as data sources. Shusi Tech’s Global Epidemic Information Monitoring System was used to analyze the data for infectious diseases, determine changes in global epidemics, determine the distribution and quantity of infectious disease cases from October 24, 2022 to November 23, 2022, and analyze their changing trends. Furthermore, the analysis of these data can be used to predict prevalence rates, and assess epidemic prevention and control measures

Global Infectious Diseases in January 2023: Monthly Analysis

Infectious diseases are a major threat to global health and the economic stability of societies worldwide. To prevent outbreaks, monitoring the growth trends of infectious diseases appears to be particularly important and necessary. Herein, data from epidemiological websites, such as the World Health Organization and National Health Council are used to illustrate the outbreak trends for infectious diseases worldwide. In the context of the COVID-19 pandemic, a global resurgence in other infectious diseases has been observed, particularly influenza in the United States. Proper surveillance and effective strategies are urgently required to keep emerging infectious diseases under control

Global Infectious Diseases in April 2023: Monthly Analysis

Thousands of years have passed since infectious diseases first endangered human health as the most potentially lethal and debilitating diseases worldwide. The global incidence of infectious diseases has increased significantly over the past decades, such as COVID-19, cholera, dengue, and influenza. Key elements in combating and controlling diseases include monitoring and reporting infectious disease timelines and geographic distribution. We obtained surveillance data from Shusi Tech’s Global Epidemic Information Monitoring System and comprehensively analyzed the timing and location of outbreaks in infected populations from 24 March 2023 to 23 April 2023. Recent worldwide outbreaks of infectious diseases highlight the need to implement effective monitoring strategies and warning systems

Global Infectious Diseases in May 2023: Monthly Analysis

In the past 5 years, there has been a growing focus on infectious diseases, such as viral infections (coronavirus, Mpox, and influenza), sudden pandemics, and persistent bacterial infections (cholera, malaria, and tuberculosis) that continue to be a challenge in epidemic areas. We analyzed epidemic data from dozens of infectious diseases between 24 April and 23 May 2023 using Shusi Tech’s Global Epidemic Information Monitoring System. This analysis will provide a quick overview of the global epidemic status, and will facilitate the prediction and assessment of future pandemics